Asthma/Obstructive Pulmonary Disease Overlap

Update on Definition, Biomarkers, and Therapeutics

August Generoso; John Oppenheimer


Curr Opin Allergy Clin Immunol. 2020;20(1):43-47. 

In This Article


Currently, a consensus definition of ACO is lacking, but reaching one is necessary in order for meaningful studies to be performed. Potential areas of study include identifying ACO biomarkers as well as determining phenotypes and endotypes. Additionally, the efficacy of current therapies (ICS, LABA, and LAMA) need to be investigated, along with other drugs that have shown benefit in asthma and/or COPD (e.g., biologics and roflumilast [phosphodiesterase inhibitor]).[29–33] As research indicates ACO to be an illness with significant prevalence, and one that leads to increased morbidity/mortality and healthcare utilization, further studies of this entity are certainly warranted.